Researcher Profile

Researcher Profile

Joseph Drabick, MD, FACP

Joseph Drabick, MD, FACP

Rose Dunlap Division Chief Chair in Hematology/Oncology, Department of Medicine
Chief, Division of Hematology and Oncology
Scientific Program:Experimental Therapeutics
Disease Teams:
Central Nervous System Cancer
Genitourinary Cancer
Immunotherapy
Melanoma and Skin Cancer
Sarcoma Cancer
jjd25@psu.edu

Research Interests

  • Therapeutics
  • Neoplasms
  • Melanoma
  • HIV
  • Haiti
  • United Nations
  • Survival
  • Skin
  • Vaccines
  • Infection
  • Immunotherapy
  • Drug Therapy

Clinical Trials

A Phase II Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrent Disease in Cutaneous Squamous Cell Carcinoma
Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Prognosis of Recurrence Risk
DecisionDx-Melanoma Gene Expression Profile Test Result to Predict Risk of Sentinel Lymph Node (SLN) Metastasis
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Enhancing Patient Resilience During Multimodal Therapy for Bladder Cancer
Definition of Somatic Variants Corresponding to Immune Targets in Patients with Metastatic Melanoma
A Retrospective Evaluation to Understand how â-adrenergic Antagonism Impacts the Progression of Melanoma and the Efficacy of Standard Treatments Intended to Eliminate the Cancer
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome

Recent Publications

2019

Zhu, J, Hussain, M, Joshi, A, Truica, C, Nesterova, D, Collins, J, Saunders, EFH, Hayes, M, Drabick, J & Joshi, M 2019, 'Effect of creative writing on mood in patients with cancer' BMJ Supportive and Palliative Care. https://doi.org/10.1136/bmjspcare-2018-001710
Jia, B, Zhao, C, Rakszawski, KL, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Wang, M, Shike, H, Bayerl, M, Sivik, JM, Schell, T, Drabick, J, Hohl, R & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107
Zaleski, M, Gogoj, A, Walter, V, Raman, J, Kaag, MG, Merrill, S, Drabick, J, Joshi, M, Holder, S, Degraff, D & Warrick, J 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system' Human Pathology, vol. 84, pp. 275-282. https://doi.org/10.1016/j.humpath.2018.10.008
Joshi, M, Warrick, J, Yin, M, Holder, S & Drabick, J 2019, 'Need for a personalized approach for muscle invasive bladder cancer: Role of tumor biology in response to neoadjuvant chemotherapy', Translational Andrology and Urology, vol. 8, pp. S99-S103. https://doi.org/10.21037/tau.2018.12.04

2018

Yin, M, Grivas, P, Emamekhoo, H, Mendiratta, P, Ali, S, Hsu, JA, Vasekar, M, Drabick, J, Pal, S & Joshi, M 2018, 'ATM/RB1 mutations predict shorter overall survival in urothelial cancer', Oncotarget, vol. 9, no. 24, pp. 16891-16898. https://doi.org/10.18632/oncotarget.24738
Sivik, JM, Davidson, J, Hale, CM, Drabick, J & Talamo, G 2018, 'Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma' Supportive Care in Cancer, vol. 26, no. 9, pp. 3055-3061. https://doi.org/10.1007/s00520-018-4165-6
Tian, Y, Fox, E, Drabick, J & Pameijer, CR 2018, 'Isolated limb infusion as a treatment option for malignant granular cell tumour' BMJ case reports, vol. 2018, 224618. https://doi.org/10.1136/bcr-2018-224618
Dinavahi, SS, Noory, MA, Gowda, R, Drabick, J, Berg, A, Neves, R & Robertson, G 2018, 'Moving synergistically acting drug combinations to the clinic by comparing sequential versus simultaneous drug administrations', Molecular pharmacology, vol. 93, no. 3, pp. 190-196. https://doi.org/10.1124/mol.117.110759
Patel, UH, Drabick, J, Malysz, J & Talamo, G 2018, 'Nonsecretory and Light Chain Escape in Patients With Multiple Myeloma' Clinical Lymphoma, Myeloma and Leukemia, vol. 18, no. 12, pp. e515-e519. https://doi.org/10.1016/j.clml.2018.06.028
Kokolus, KM, Haley, JS, Koubek, EJ, Gowda, R, Dinavahi, SS, Sharma, A, Claxton, D, Helm, K, Drabick, J, Robertson, G, Neighbors, J, Hohl, R & Schell, T 2019, 'Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity', OncoImmunology, vol. 8, no. 2, e1539614. https://doi.org/10.1080/2162402X.2018.1539614
Ribas, A, Medina, T, Kummar, S, Amin, A, Kalbasi, A, Drabick, J, Barve, M, Daniels, GA, Wong, DJ, Schmidt, EV, Candia, AF, Coffman, RL, Leung, ACF & Janssen, RS 2018, 'Sd-101 in combination with pembrolizumab in advanced melanoma: Results of a phase ib, multicenter study', Cancer Discovery, vol. 8, no. 10. https://doi.org/10.1158/2159-8290.CD-18-0280

2017

Kokolus, KM, Zhang, Y, Sivik, JM, Schmeck, C, Zhu, J, Repasky, EA, Drabick, J & Schell, T 2018, 'Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice', OncoImmunology, vol. 7, no. 3, e1405205. https://doi.org/10.1080/2162402X.2017.1405205
Kuzu, OF, Gowda, R, Sharma, A, Noory, MA, Kardos, G, Madhunapantula, SRV, Drabick, J & Robertson, G 2018, 'Identification of WEE1 as a target to make AKT inhibition more effective in melanoma', Cancer Biology and Therapy, vol. 19, no. 1, pp. 53-62. https://doi.org/10.1080/15384047.2017.1360446
Koller, KM, Mackley, H, Liu, J, Wagner Jr., H, Talamo, G, Schell, T, Pameijer, CR, Neves, R, Anderson, B, Kokolus, KM, Mallon, CA & Drabick, J 2017, 'Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone', Cancer Biology and Therapy, vol. 18, no. 1, pp. 36-42. https://doi.org/10.1080/15384047.2016.1264543
Kuzu, OF, Gowda, R, Sharma, A, Noory, MA, Dinavahi, SS, Kardos, G, Drabick, J & Robertson, G 2017, 'Improving pharmacological targeting of AKT in melanoma', Cancer Letters, vol. 404, pp. 29-36. https://doi.org/10.1016/j.canlet.2017.07.001
Teye, EK, Sido, A, Xin, P, Finnberg, NK, Gokare, P, Imamura, Y, Salzberg, AC, Shimko, S, Bayerl, M, Ehmann, WC, Claxton, D, Rybka, W, Drabick, J, Wang, H-G, Abraham, T, El-Deiry, WS, Brodsky, RA, J.Hohl, R & Pu, J 2017, 'PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features' Oncotarget, vol. 8, no. 18, pp. 29887-29905. https://doi.org/10.18632/oncotarget.15136
Yin, M, Wang, W, Drabick, J & Harvey, H 2017, 'Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: A comparative study', BMC Cancer, vol. 17, no. 1, 295. https://doi.org/10.1186/s12885-017-3292-7

2016

Matthew, EM, Zhou, L, Yang, Z, Dicker, DT, Holder, S, Lim, B, Harouaka, R, Zheng, S, Drabick, J, Lamparella, NE, Truica, C & El-Deiry, WS 2016, 'A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells', Oncotarget, vol. 7, no. 4, pp. 3662-3676. https://doi.org/10.18632/oncotarget.6657
Baker, M, Goldstein, AM, Gordon, P, Harbaugh, K, Mackley, H, Glantz, M & Drabick, J 2016, 'An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies', Journal of medical genetics, vol. 53, no. 11, pp. 721-727. https://doi.org/10.1136/jmedgenet-2015-103446
Al-Marrawi, MY, Mackley, H, Ali, S, Wagner Jr., H, Joshi, M, Holder, S, Kaag, MG, Mallon, C, Talamo, G & Drabick, J 2016, 'Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review', Clinical Genitourinary Cancer, vol. 14, no. 4, pp. e393-e399. https://doi.org/10.1016/j.clgc.2016.01.004
Koller, KM, Wang, W, Schell, T, Cozza, EM, Kokolus, KM, Neves, R, Mackley, H, Pameijer, CR, Leung, A, Anderson, B, Mallon, CA, Robertson, G & Drabick, J 2016, 'Malignant melanoma—The cradle of anti-neoplastic immunotherapy', Critical Reviews in Oncology/Hematology, vol. 106, pp. 25-54. https://doi.org/10.1016/j.critrevonc.2016.04.010
Joshi, M, Millis, SZ, Arguello, D, Holder, S, Lamm, D, Reddy, S, Belani, C, Drabick, J & Vogelzang, NJ 2018, 'Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers', European Urology Focus, vol. 4, no. 1, pp. 94-97. https://doi.org/10.1016/j.euf.2016.06.011
Yin, M, Joshi, M, Meijer, RP, Glantz, M, Holder, S, Harvey, H, Kaag, MG, Van De Putte, EEF, Horenblas, S & Drabick, J 2016, 'Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis', Oncologist, vol. 21, no. 6, pp. 708-715. https://doi.org/10.1634/theoncologist.2015-0440
Joshi, M, Pal, SK & Drabick, J 2016, 'Novel approaches in cancer immunotherapy - A light at the end of the tunnel', Discovery medicine, vol. 21, no. 118.
Yin, M, Mackley, H, Drabick, J & Harvey, H 2016, 'Primary female breast sarcoma: Clinicopathological features, treatment and prognosis', Scientific reports, vol. 6, 31497. https://doi.org/10.1038/srep31497
Joshi, M, Vasekar, M, Grivas, P, Emamekhoo, H, Hsu, JA, Miller, VA, Stephens, PJ, Ali, SM, Ross, JS, Zhu, J, Warrick, J, Drabick, J, Holder, S, Kaag, MG, Li, M & Pal, SK 2016, 'Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma', Oncotarget, vol. 7, no. 32, pp. 52442-52449. https://doi.org/10.18632/oncotarget.9449
Yin, M, Wang, W, Rosenberg, J, Kaag, MG, Joshi, M, Holder, S, Tuanquin, L & Drabick, J 2016, 'Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review', Clinical Genitourinary Cancer, vol. 14, no. 2, pp. e203-e206. https://doi.org/10.1016/j.clgc.2015.11.008

2015

Dao, M, Suresh, S, Huang, TJ, Li, P, Mao, Z, Peng, Z, Zhou, L, Chen, Y, Huang, PH, Truica, C, Drabick, J & El-Deiry, WS 2015, 'Acoustic separation of circulating tumor cells', Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 16, pp. 4970-4975. https://doi.org/10.1073/pnas.1504484112
Holder, S, Drabick, J, Zhu, J & Joshi, M 2015, 'Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer' Cancer Biology and Therapy, vol. 16, no. 2, pp. 207-209. https://doi.org/10.1080/15384047.2014.1002687
Wyluda, EJ, Cheng, J, Schell, T, Haley, JS, Mallon, C, Neves, R, Robertson, G, Sivik, J, Mackley, H, Talamo, G & Drabick, J 2015, 'Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy' Cancer Biology and Therapy, vol. 16, no. 5, pp. 662-670. https://doi.org/10.1080/15384047.2015.1026507
Al-Marrawi, MY, Cream, L, Mallon, CA, Holder, S, Joshi, M, Harvey, H, Talamo, G & Drabick, J 2015, 'Effect of topical vaginal androgens in a woman on the testosterone levels of her sexual partner with prostate cancer' Journal of Clinical Oncology, vol. 33, no. 5, pp. 521-522. https://doi.org/10.1200/JCO.2014.59.7773
Wang, W, Cheng, J, Mallon, C, Al-Marrawi, MY, Holder, S, Joshi, M, Kaag, MG, Talamo, G & Drabick, J 2015, 'Symptomatic secondary polycythemia induced by anti-VEGF therapy for the treatment of metastatic renal cell carcinoma: A case series and review' Clinical Genitourinary Cancer, vol. 13, no. 6, pp. e391-e395. https://doi.org/10.1016/j.clgc.2015.07.003
Lipkin, JS, Rizvi, SM, Gatalica, Z, Sarwani, N, Holder, S, Kaag, MG, Drabick, J & Joshi, M 2015, 'Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression' Cancer biology & therapy, vol. 16, no. 1, pp. 28-33. https://doi.org/10.4161/15384047.2014.972843

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)